Home
INMB

INMB

INmune Bio Inc.

as of 12-12-2025 3:38pm EST

$2.03

$0.11

-5.14%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Chart Type:

Time Range:

Founded:	2015	Country:	United States
Employees:	N/A	City:	BOCA RATON
Market Cap:	49.2M	IPO Year:	2019
Target Price:	$4.30	AVG Volume (30 days):	507.4K
Analyst Decision:	Hold	Number of Analysts:	3
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-2.11	EPS Growth:	N/A
52 Week Low/High:	$1.38 - $11.64	Next Earning Date:	10-30-2025
Revenue:	$50,000	Revenue Growth:	19.05%
Revenue Growth (this year):	173.21%	Revenue Growth (next year):	12733.99%

AI-Powered INMB Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold

Model Accuracy: 71.14%

71.14%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full INMB Forecast & Prediction with Hourly Data

Compare INMB vs Leading Stocks

See how INMB stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free INMB Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "INMB INmune Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.